Index

Note: Page number followed by f and t denotes figure and table respectively.

Ablatherm™, 202
active surveillance (AS), 120, 136, 142–3, 192–3
candidates for, 137, 138t
future perspective, 141–2
imaging in, 102–3
for low-risk prostate cancer management, 136
patient monitoring in, 137, 139
results of, 139–141, 140t
adenomatous polyposis coli (APC), 61
ADT, see androgen deprivation therapy (ADT)
African-Americans, 3
age
and decision-making in prostate cancer, 118–19
as risk factor, 2
alcohol consumption, 5
α-tocopherol, 7
alpha-methylacyl-coenzyme A racemase (AMACR), 35, 36f, 64
Alpharadin, 278
American Cancer Society (ACS), 27, 51
American Society for Therapeutic Radiology and Oncology, 213
American Society of Clinical Oncology (ASCO), 125, 213
American Urological Association (AUA), 27–9, 51, 125, 127–9, 161, 191, 199, 212
aminolevulinic acid (ALA), 205
anastomotic stricture, 158
anastomotic urinary leakage, 158
androgen deprivation therapy (ADT), 128, 131–2, 200, 223, 231, 233, 245, 249–50, 265
checklist for monitoring patients, 257t
future therapeutic strategies, 258
modality of, 252–3
and nodal irradiation, 174–5
side effects of, 256
timing of, 250–52
androgen receptor activation mechanisms, 273–4
amplification, 273
mutations, 273
splice variants, 273
androgens, role of, in prostate cancer development, 4
annexin A3 (ANXA3), 61–2
antiandrogens, 271
anti-PD1therapy, 276
artificial urinary sphincter insertion, 162
AS, see active surveillance (AS)
atypia suspicious for prostate cancer (ASAP), 36–7
BCR, see biochemical recurrence (BCR)
bicalutamide, 130
bilateral orchidectomy, 131
biochemical recurrence (BCR), 161, 213–14
Biofeedback, 162
biopsy, see also transrectal ultrasound-guided biopsy (TRUS-Bx)
for monitoring disease recurrence, 214–15
for prostate cancer diagnosis, 20–21
bisphosphonates, 288–9
blood-based biomarkers, 55
human glandular kallikrein 2, 55
interleukin-6 and receptor, 56
transforming growth factor-beta 1, 56
urokinase plasminogen activator, 56
bone scintigraphy
for monitoring disease recurrence, 215
role in prostate cancer imaging, 72, 73t
Index

brachytherapy, 178
advantage of, 178
with EBRT, 179–80, 183–4
forms of, 179
HDR brachytherapy, 180
LDR seed brachytherapy, 179
patient selection for, 179
procedure, 180–81
results, 181–4
side effects of, 185
acute toxicity, 185
late effects, 185
Bragg peak, 178
BRCA1/BRCA2 mutations, and risk of prostate
cancer, 7
cabazitaxel, 279–80
calcium intake, and prostate cancer, 6–7
Canadian Urological Association (CUA), 125
Cancer Prevention Study II Nutrition Cohort, 6
Castrate Resistant Prostate Cancer (CRPC), 66, 287
castration resistant prostate cancer (CRPC), 245, 265
cell search system, 66
Charlson co-morbidity index, 119
choline-based nuclear medicine studies in
staging, 100, 102
chromogranin A (CGA), 57
chromosomal aberrations, in prostate tumors,
65
chromosome 8p22 loss and 8q24 gain, 65
circulating tumor cells (CTCs), 66
clinical nurse specialists, role of, in prostate
cancer, 124–5
clinical practice guidelines, 125
for localized prostate cancer, 125
high-risk disease, 128–9
intermediate-risk disease, 127–8
low-risk disease, 127
risk stratification in, 126
treatment options, 126
very low risk disease, 126–7
for locally advanced disease, 129
cT3b-T4 nonmetastatic prostate cancer,
129–31
metastatic prostate cancer, 131–2
cancer, 9–10
contrast-enhanced ultrasound (CEUS), 76–7
counterbalanced radiotherapy, 171. See also
radiation therapy
COU-AA-301, 269
Cryo On-Line Database (COLD), 199
cryotherapy, 198–9
focal therapy results, 200–201
whole-gland results, 199–200
CTLA-4 blockade, 275
cyclin-dependent kinase inhibitor 1B
(CDKN1B), 65
CYP3A4 inducers, 270
cytokeratins, 35, 64
decision aids, 124
decision-making, in prostate cancer
management, 116–17
clinical nurse specialists, role of, 124–5
clinical practice guidelines for, 125
localized prostate cancer and, 125–9
locally advanced disease, 129–32
decision aids, use of, 124
factors influencing
age and co-morbidity, 118–19
chance of cure and risk of recurrence, 118
family and friends, 121–2
financial issues, 123–4
patient beliefs and misconceptions, 120
physician recommendation and bias,
122–3
stage of disease, 118
treatment choice in localized disease, 120
treatment-induced morbidity, 120–21
lack of level one evidence and, 117–18
primary care physician, role of, 125
shared, 116–17
deep venous thrombosis (DVT), 159
diagnosis of prostate cancer, 17–18
digital rectal examination, 19
digital rectal examination-guided biopsy,
20–21
diagnosis, 17–18
digital rectal examination, 19
digital rectal examination-guided biopsy,
20–21
diet, and prostate cancer, 5–6
digital rectal examination (DRE), 17, 23, 28,
29, 49, 127, 147, 211, 216–18
for monitoring disease recurrence, 214
for prostate cancer presence, 19–20
DNA-based urine biomarkers, 60–61
dorsal venous complex (DVC), 145
DRE, see digital rectal examination
(DRE)
dutasteride, 17
ED, see erectile dysfunction (ED)
elastography, 77, 78f–80f
elderly, and prostate cancer, 2
endorectal MRI (eMRI), 222
environment, role of, 2
enzalutamide, 271–2
epidemiology
conservative management, 9
geographical differences, 2
incidence, 1
mortality and survival, 1–2
natural history of disease, 8–9
risk factors
aging, 2
diet, 5–6
family history, 3–4
genetic variations, 7
hormonal factors, 4
lifestyle decisions, 5
race/ethnicity, 3
vitamins and minerals, 6–7
erectile dysfunction (ED)
after brachytherapy, 185–6
after RP, 162–3, 163t
European Association of Urology (EAU), 29, 77, 125–32, 212, 218
European Prospective Investigation into Cancer and Nutrition (EPIC) study, 5–6
European Randomized Study of Screening for Prostate Cancer (ERSPC), 23–5, 28–9, 245
European Society for Medical Oncology (ESMO), 125, 213
external beam radiotherapy (EBRT), 119, 170–72
family history, as risk factor, 3
fat consumption, and prostate cancer risk, 5–6
financial influences, on treatment decisions, 123–4
finasteride, 4
fistula formation, after brachytherapy, 186
local therapy, 194–5. See also specific therapy
Food and Drug Administration (FDA), 300
follow-up, posttreatment, 212, 222f
evidence acquisition on, 212–13
first intervention against treatment failure, 221–3, 224f. See also recurrences
functional follow-up, 219
after EBRT and brachytherapy, 220–21
after RP for localized tumor, 219–20
imaging for, 104–6
monitoring tools
bone scintigraphy, 215
computed tomography, 215–16
digital rectal examination, 214
magnetic resonance imaging, 215–16
positron emission tomography, 215
prostate-specific antigen, 213–14
TRUS and biopsy, 214–15
oncological follow-up
after AS, 216
brachytherapy and, 218
cryotherapy and, 218
e external beam radiotherapy and, 217–18
HIFU and, 218
after RP for localized tumor, 216–17
free PSA (PSA), 53
gamma-semioprotein, see prostate-specific antigen (PSA)
genomic-based biomarkers, 63
GETUG-01 trial, 173
Gleason grading system, 20–21
Gleason score, 37–8
glutathione-S-transferase- π (GSTP1), 60–61
GnRH antagonists, 131
GOLPH2, 60
Göteborg Sweden Trial, 26
health-related quality of life (HRQOL), 141, 219
hemiatblation, of prostate cancer lesions, 195, 197f
hemorrhage, radical surgery and, 157
hepatocyte growth factor, 278
heritable causes, of prostate cancer, 4
HIFU, see high-intensity focused ultrasound (HIFU)
high dose rate (HDR) brachytherapy, 179.
See also brachytherapy
patient selection for, 180
procedure, 180–81
results of, 183
high-intensity focused ultrasound (HIFU), 201–202, 201f
local therapy results, 203, 204f
whole-gland results, 202–203
histological variants, of prostate cancer, 34
histopathology, of prostate cancer
data from radical prostatectomy specimen, 42–5
errors reporting, 40
Gleason scores, 37–8
histological variants, 34
lymph nodes, 46
perineural invasion, 39
prognostic markers, 46–7
prostate cores, 35–7
prostate histology and immunohistochemistry, 35
quality of cores, 39–40
radical prostatectomies, 41–2
transurethral resection specimens, 40–41
volume of tumor in cores, 38–9
hormonal therapy
for locally advanced disease, 129–30
for PSA recurrence after RP/RT, 240
hormone relapsed disease
abiraterone acetate, 268
CYP17 inhibition, 268
phase III CRPC trials, 266t
Index

hormone relapsed disease (Continued)
practical considerations, 270
targeting androgen receptor signaling, 268
treatment paradigm with CRPC, 267
human glandular kallikrein 2 (hK2), 55
Hybritech Tandem-R PSA test, 49
8-hydroxy deoxyguanosine (8-OHDG), 61
hypofractionation in radiotherapy, 176–7
imaging, 72
for detection and diagnosis, 73
biopsy techniques, 85–8
multiparametric MRI (mpMRI), 80–85
transperineal prostate biopsies, 73, 74f, 80
transrectal ultrasound-guided biopsy, 73–80
follow-up of cancer under treatment, 104–6
modalities for, 72, 73t
modifying treatment by, 102–4
role of, in prostate cancer, 72, 73t
for staging and treatment determination, 89
choline-based nuclear medicine studies, 100–102
M stage, 99–100
N stage, 97–9
T stage, 89–97
immunohistochemistry, 35, 36f
IMRT, see intensity-modulated radiotherapy (IMRT)
incidence, 1, 8
African-Americans, 3
geographical differences, 2
of low-risk prostate cancer, 136
inferior vena cava (IVC) filter, 159
insulin-like growth factor binding protein-3 (IGFBP-3), 57
insulin-like growth factors (IGFs), 4, 56
intensity-modulated radiotherapy (IMRT), 171–2, 173f
See also radiation therapy interleukin-6 (IL-6), 56
intermittent androgen deprivation (IAD), 131, 254
International Index of Erectile Function-15 (IIEF-15) scores, 205
International Prostate Symptoms Score (IPSS) questionnaire, 205
intraurethral/intracavernosal vasodilators, 163
inverse planning techniques, 172
irreversible electroporation (IRE), 206
Japanese Urological Association (JUA), 29
Kallikrein-3 (KLK3), see prostate-specific antigen (PSA)
Ki-67 antigen, 65
laparoscopic radical prostatectomy (LRP), 146, 147
laser photothermal therapy, 206–7
leucopenia, 290
life tables, 118–9
linear accelerators, 171
localized prostate cancer:
clinical practice guidelines for, 125
high-risk disease, 128–9
intermediate-risk disease, 127–8
low-risk disease, 127
risk stratification in, 126
treatment options, 126
very low risk disease, 126–7
novel therapies for, 191–3
cryotherapy, 198–201
focal therapy, 194–5
high-intensity focused ultrasound, 201–3, 201f
irreversible electroporation, 206
laser photothermal therapy, 206–7
minimally invasive treatment, 193–4
photodynamic therapy, 203–6
low dose rate (LDR) permanent seed brachytherapy, 179. See also brachytherapy
patient selection for, 179
procedure, 180
results of, 181–3, 182f
low-risk prostate cancer, 136. See also active surveillance (AS)
luteinizing-hormone-releasing hormone (LHRRH), 301
lycopene, 6
lymphadenectomies, 46
magnetic resonance imaging (MRI), 248
magnetic resonance lymphangiography (MRL), 98–9
matrix metalloproteinases (MMPs), 62
maximal androgen blockade (MAB), 131
metabolite urine markers, 62–3
Metastatic Prostate Cancer, diagnosis and management of, 246–79
Alpharadin, 278
Cabozantinib, 278–9
diagnosis of, 246–7
future of, 249
initial treatment of, 249
Ipalimumab, 275–6
role of bone-targeted agents, 256
Sipuleucel-T, 274–5
microsemionprotein-beta (MSMB), 62
minimally invasive treatment, for prostate cancer, 193–4. See also specific treatment
success and failure after, 195, 197, 198t
mortality rates
African-Americans, 3
decline in, 1–2
geographical variations in, 2
MRC RT01 trial, 173
multidisciplinary team (MDT) review, 122–3
multiparametric magnetic resonance imaging (MP-MRI), 80–81
for detection and diagnosis, 80–88
diffusion-weighted imaging (DWI), 81
dynamic contrast enhancement (DCE), 81
index lesion by, detection of, 195
for low-risk prostate cancer detection, 142
magnetic resonance spectroscopy (MRS), 81–2
minimum standards for, 84t
for staging and treatment determination
M stage, 99, 100
N stage, 97–9
T stage, 89–97
strategies for using MRI map during biopsy, 85
cognitive ultrasound-guided biopsy, 85–6
fusion of mpMRI dataset on TRUS, 86–7, 87f, 88f
MRI-guided biopsy, 86
TRUS-Bx limitations and, 82–5
cognitive ultrasound-guided biopsy, 85–6
fusion of mpMRI dataset on TRUS, 86–7, 87f, 88f
MRI-guided biopsy, 86
TRUS-Bx limitations and, 82–5
use as combination of sequences, 82, 83f

National Cancer Institute, 213
National Comprehensive Cancer Network (NCCN), 27, 125–9, 213
National Guidelines Clearinghouse, 212–3
National Institute for Health and Clinical Excellence (NICE), 123, 125, 127, 213
natural history, of prostate cancer, 8
nerve sparing (NS) technique, 150–52, 151f
neuron-specific enolase (NSE), 57
New Zealand National Health Committee (NHC), 29
N-methylglycine, 62–3
nucleic acid detection immunoassay (NADIA) ProsVue, 54–5
Nutritional Prevention of Cancer Study, 7
obesity, 5
p27, see cyclin-dependent kinase inhibitor 1B (CDKN1B)
p63, 64
PAP, see prostatic acid phosphatase (PAP)
partners, role in decision-making process, 121–2
patients beliefs, and treatment choice, 120
PCA3-Gene-Viro Therapy study, 59
PCA3 urine assay, 30
PDE-5 inhibitors, 163
PDT, see photodynamic therapy (PDT)
penile implants, 163
pentafecta, 220
percent free PSA (fPSA), 50, 53
perineural invasion, 39
periurethral space, 146
periprostatic space, 162
PET scan, 302
phosphodiesterase inhibitors, 186
photodynamic therapy (PDT), 203, 205–6
physician bias
overcoming of, methods for, 122–3
role in decision-making process, 122
Physicians’ Health Study II, 7
PINAtyp, 37
PIVOTAL trial, 175
PIVOT study, 26–7, 192
PLCO screening trial, 23–4, 29
positron emission tomography (PET), 215, 222, 248
predictive tools, for patient counseling, 118
primary care physician, role of, in prostate cancer, 125
[–2]proenzyme PSA (p2PSA), 54
PROGENSA PCA3, 58
ProPSA, 54
prostate cancer, 1, 8–9, 16–17, 211–12, 287–326
bonemetastases, 288
bonepain, 288
bone-targeted radio-isotopes, 289
chemoprevention, 319
deaths by age and place, 294f
future of diagnosis, 314–15
genetic markers of familial and sporadic, 318–19
heterogeneity, 321–2
long perspective, 298
management of end-stage, 291–2
palliative and supportive care, 292–4
serumbiomarkers, 315–18
spinal cord compression, 289
stem cell biology, 320f
treatment protocols, 326f
treatments for, 322, 323f
prostate cancer antigen 3 (PCA3), 58–9
prostate cancer (PCa) cells, 49
tumor markers in, 49. See also tumor markers
Prostate Cancer Prevention Trial, 4
Prostate Cancer Research International Active Surveillance (PRIAS), 137
prostatectomy, 146. See also radical prostatectomy (RP)
Prostate Health Index (PHI), 54
Index

prostate imaging-reporting and data system (Pr-RADS), 93–7
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, 23
prostate-specific antigen (PSA), 18–19, 35, 50, 230, 268
as biomarker, 49–50. See also PSA biomarker detection
for monitoring disease recurrence, 213–14
recurrence after RP and RT, and hormonal therapy, 240
rising PSA, management of, 230–32
in post-RP patients, 233–8
in post-RT patients, 238–40
in treatment naive patients, 232–3
screening, 1, 8, 10
prostate-specific membrane antigen (PSMA), 65
prostate stem cell antigen (PSCA), 66
prostatic acid phosphatase (PAP), 18, 57
prostatic adenocarcinoma, 37
prostatic apex, 152
prostatic intraepithelial neoplasia (PIN), 36
prostatovesical junction (PVJ), 150
PROTecT study, 139
protein markers, in urine, 61
annexin 3, 61–2
matrix metalloproteinases, 62
microseminoprotein-beta, 62
proton therapy, 178
PR07 trial, 175
PSA, see prostate-specific antigen (PSA)
PSA biomarker detection, 49–50, 52
inactive PSA, 53
limitations with, 50–51
percent free PSA, 53
[–2]proPSA, 54
ProPSA protein, 54
PSA isoforms, 54
PSAV and PSADT, 53
total PSA (tPSA), 50
PSA bounce, 182, 218
PSA doubling time (PSADT), 53
PSA velocity (PSAV), 50, 53
PTEN, 64–5
pulmonary embolism, 159
pulsed dose rate (PDR), 179
quadrant ablation, of prostate cancer lesions, 195, 197f
Quebec Prospective Randomized Controlled Trial, 23
Quebec Prostate Cancer Trial, 23
race, as risk factor, 3
radiation fractionation, 176
radiation proctitis, 186
Radiation Therapy Oncology Group (RTOG) 94-13 trial, 175
radiation therapy (RT), 170, 191
adjuvant/salvage, 176
androgen deprivation therapy and, 174–5
brachytherapy, 178–86
dose escalation, benefits of, 172–4
external beam radiotherapy, 170–72
hypofractionation in, 176–7
for locally advanced disease, 130
proton therapy, 178
stereotactic body radiotherapy, 177–8
radical prostatectomy (RP), 41, 119, 145–6.
See also robot-assisted laparoscopic prostatectomy (RALP)
complications of, 157
anastomotic stricture, 158
hemorrhage, 157
infection, 158
lymphocele, 159
rectal injury, 157
rectourethral fistula, 159
thrombosis, 159
ureter injury, 157–8
urethrovessical anastomotic urinary leakage, 158
goals of, 146
for locally advanced disease, 130
minimally invasive approaches
laparoscopic radical prostatectomy, 147
robot-assisted laparoscopic radical prostatectomy, 147
open approaches
radical perineal prostatectomy, 147
radical retropubic prostatectomy, 146
outcomes
functional outcomes, 162–3, 162t, 163t
oncological, 160–61, 160t
perioperative, 159
specimens for tumor banking, 41
data from, 42–5
fresh, 41
Gleason score, 43
location and multiplicity, 42–3
margin status, 44–5, 45f
perineural invasion and vascular invasion, 44
processing of, 41
staging of tumor, 43–4
volume of tumor, 43
types of, 146–7
Radical prostatectomy outcomes, anatomical, 299–300, 307
Radical Prostatectomy versus Observation for Localized Prostate Cancer (PIVOT) studies, 117–18
radical retropubic prostatectomy (RRP), 145, 146
RADICALS trial, 176
RALP, see robot-assisted laparoscopic prostatectomy (RALP)
randomized control trials (RCTs), 21, 23
rectal injury, radical surgery and, 157
rectourethral fistula, 159
recurrences, 212
after RP, 221–3
after RT, 223
Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, 17, 58–9
retinoic acid receptor/β2 (RARβ2), 61
RMH pilot study, 173
RNA markers, in urine, 58
GOLPH2, 60
PCA3 gene, 58–9
SPINK1, 60
telomerase reverse transcriptase, 60
TMPRSS2-ERG fusion gene, 59
robot-assisted laparoscopic prostatectomy (RALP), 123, 145–7
complications of, 157–9
contraindications, 147
indications, 147
instrumentation, 148
patient positioning, 148–9
port placement, 149
postoperative management, 157
preoperative workup, 147
transperitoneal anterior approach, 149
anastomosis and anterior repair, 154
circumapical dissection of urethra, 152–4, 153f
dropping the bladder, 149–50
dynamic detrusor cuff trigonoplasty, 154, 155f
nerve sparing (NS), 150–52, 151f
posterior reconstruction, 154
seminal vesicles and vas deferens dissection, 150
suprapubic catheter placement, 154, 156f
RP, see radical prostatectomy (RP)
RT, see radiation therapy (RT)
salvage cryosurgical ablation of prostate, 239–40
salvage high-intensity focused ultrasound (HIFU), 240
Salvage RP (SRP), 239
Salvage RT (SRT) therapy, 236–8
Salzburg statement, on shared decision-making, 116–17
samarium-153, 289
saturation biopsies, 77
Scandinavian Prostate Cancer Group-4 trial (SPCG-4), 117, 192
screening criteria for population screening, 21
acceptability of test, 22
case selection, 22
costs, 22
diagnostic tests, 21
epidemiology, 21
natural history, 21
resources and services, 22
treatment, 22
recommendations from international health organizations
European and International screening guidelines, 29–30
USA screening guidelines, 27–9
trials and RCTs for, 23–7
Selenium and Vitamin E Cancer Prevention Trial (SELECT), 7, 17
selenium supplementation, 7, 17
sexual dysfunction, 120–21
side-effects of treatment, and treatment decision-making process, 120–21
sildenafil, 186
single-nucleotide polymorphisms (SNPs), 7, 63
skin sparing effect, 171
smoking, and prostate cancer, 5
Sonablate500™, 202
Southwest Oncology Group (SWOG), 255
soy, and prostate cancer risk, 6
SPCG-7 trial, 174–5
SPINK1, 60
statistical nomograms, 119
stereotactic body radiotherapy (SBRT), 177–8
strontium-89, 289
subtotal ablation, of prostate cancer lesions, 195, 197f
Surveillance Epidemiology and End Results (SEER) database, 1
survival rates, rise in, 1–2
Swedish national healthcare system, 124
SWOG 8794 trial, 176
symptoms, prostate cancer and, 17
tadalafil, 186
technetium-based bone scintigraphy, 99
telomerase reverse transcriptase (TERT), 60
temporary afterloading brachytherapy, 179
three-dimensional conformal radiotherapy (3D-CRT), 171–2, 172f.
see also radiation therapy
three-dimensional template prostate mapping (TPM), 195, 196f
Index

thrombocytopenia, 290
TMPRSS2-ERG fusion gene, 59
TNM system, for staging of prostate cancer, 21
total PSA (tPSA), 50
transcutaneous electrical nerve stimulation, 162
transforming growth factor-beta 1 (TGF-β1), 56
transperineal prostate biopsies, 73, 74f, 80, 193
transrectal ultrasound, for diagnosis of prostate cancer, 20
transrectal ultrasound-guided biopsy (TRUS-Bx), 20–21, 73–80
for detection and diagnosis, 73–80
limitations of, 74–5
for monitoring disease recurrence, 214–15
for prostate cancer detection, 73
for staging and treatment determination
T stage, 89, 90f
techniques to improve conspicuity on, 75
color and power Doppler, 75
contrast-enhanced ultrasound, 76–7
detection on grayscale ultrasound, 75, 76f
elastography, 77, 78f–80f
trifecta, 220
ture focal ablation, of prostate cancer lesions, 195, 197f
tumor markers, 49, 51–2
cellular markers, 63–6
genenetic markers, 63
molecular urine markers, 57–63
prostate-specific antigen as, 49–50
and problems with PSA test, 50–51
serum or whole-blood biomarkers, 52–7
ulceration, after brachytherapy, 186
United Kingdom National Health Services (UK NHS), 29
United States Preventive Services Task Force (USPSTF), 27–9, 51
ureteral injuries, radical surgery and, 157–8
urethral strictures, after brachytherapy, 185
urethritis, after brachytherapy, 185
urinary incontinence, after RP, 161–2, 162t
urinary leakage, anastomotic, 158
urinary retention, after brachytherapy, 185
urine biomarkers, 57–8
DNA-based, 60–61
metabolite, 62–3
protein-based, 61–2
RNA-based, 58
GOLPH2, 60
PCA3 gene, 58–9
SPINK1, 60
telomerase activity, 60
TMPRSS2-ERG fusion gene, 59
urokinase plasminogen activator (uPA), 56
USA screening guidelines, 27–9
US Food and Drug Administration (FDA), 49
US Multiethnic Cohort Study, 6
US Preventive Task Force, 308
vacuum erection devices, 163
vitamin D intake, and prostate cancer, 6
vitamin E, and prostate cancer, 7, 17
volume of cancer in cores, 38–9
watchful waiting, concept of, 9–10, 136
whole-body MRI (WB-MRI), 249
WST-11 Tookad® Soluble, 205